# Michael J. Cork

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-j-cork/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,624 |
| Field | Dermatology and Skin Diseases |
| h-index | 74 |
| i10-index | 190 |
| Last Known Institution | Sheffield Children's NHS Foundation Trust |
| OpenAlex ID | https://openalex.org/A5026963044 |
| ORCID iD | https://orcid.org/0000-0003-4428-2428 |
| Works | 392 |

## Researcher papers

Showing 12 of 13.

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1](https://scholariq.org/papers/a-genome-wide-association-study-identifies-new-psoriasis-susceptibility-loci-and/)
- [Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity](https://scholariq.org/papers/identification-of-15-new-psoriasis-susceptibility-loci-highlights-the-role-of/)
- [Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*](https://scholariq.org/papers/tralokinumab-for-moderate-to-severe-atopic-dermatitis-results-from-two-52-week/)
- [New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene–environment interactions](https://scholariq.org/papers/new-perspectives-on-epidermal-barrier-dysfunction-in-atopic-dermatitis-gene/)
- [Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-abrocitinib-in-adults-and-adolescents-with-moderate-to/)
- [Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t](https://scholariq.org/papers/dupilumab-with-concomitant-topical-corticosteroid-treatment-in-adults-with/)
- [ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children](https://scholariq.org/papers/etfad-eadv-eczema-task-force-2020-position-paper-on-diagnosis-and-treatment-of/)
- [Conjunctivitis in dupilumab clinical trials](https://scholariq.org/papers/conjunctivitis-in-dupilumab-clinical-trials/)
- [Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-with-concomitant-topical-corticosteroids-in/)
- [Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial](https://scholariq.org/papers/daily-emollient-during-infancy-for-prevention-of-eczema-the-beep-randomised/)
- [When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council](https://scholariq.org/papers/when-does-atopic-dermatitis-warrant-systemic-therapy-recommendations-from-an/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Food Allergy and Anaphylaxis Research](https://scholariq.org/topics/food-allergy-and-anaphylaxis-research/)

## Researcher university

- [Sheffield Children's NHS Foundation Trust](https://scholariq.org/institutions/sheffield-children-s-nhs-foundation-trust/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.